An interventional study of MIED and PMR in Emotional Distress, Anxiety and Depression, sponsored by Peking University. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Peking University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Depression by Peking University — 10 open to participants now, 13 under way, none of them phase 3. Depression · Peking University.
Among the 21 studies in Depression by Peking University, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 19 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 19th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →10 of the 21 studies in Depression by Peking University are open now, in 1 country. Recruiting first, the newest first:
Peking University · Sites in China
Ages 18–65
Peking University · Sites in China
Ages 18+
Peking University · Sites in China
Ages 10–18 · Healthy volunteers
Peking University · Sites in China
Ages 14–60
Peking University · Sites in China
Ages 18–45
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 200 across the 20 interventional studies, 7,000 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University is the lead sponsor of 420 studies on the registry; 124 are open to participants now.
4 of the studies in Depression by Peking University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07692269Peking UniversityMindfulness Intervention for Emotional Distress: An EEG Study | 2026-12 |
| NCT07809737Peking UniversityThe Dynamic Mechanism of Mindfulness Intervention for Emotional Distress (MIED) Based on Ecological Moment Measurement | 2026-12-01 |
| NCT07480525Peking UniversityEfficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder | 2026-12-31 |
| NCT06831435Peking UniversityEffectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study | 2026-12-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Depression by Peking University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized controlled trial examining the efficacy and neural mechanisms of a standardized Mindfulness Intervention for Emotional Distress (MIED) in adults with subclinical emotional distress. One hundred and sixty participants will be randomly assigned to either an 8-week MIED program or an 8-week Progressive Muscle Relaxation (PMR) active control. The primary aim is to evaluate whether MIED reduces anxiety symptoms and reshapes multilevel emotional processing as measured by multimodal EEG (resting-state FAA/theta, Fast Periodic Visual Stimulation, and event-related potentials). Assessments occur at baseline (T1), post-intervention (T2), and 1-month follow-up.
Background. Emotional distress is a subclinical mental health condition characterized by persistent anxiety, depression, stress, and emotion dysregulation. Mindfulness interventions have shown efficacy across transdiagnostic emotional disorders, yet their neurocognitive mechanisms remain incompletely understood.
Objective. This study aims to (1) verify the dynamic intervention effects of MIED on emotional distress; (2) reveal neuroplastic changes across multiple levels of emotional processing; (3) explore associations between neural changes and symptom improvement; and (4) examine whether strategy acquisition is linked to neural remodeling.
Design. This is a two-arm, parallel-group, randomized controlled trial with single (outcomes assessor) blinding. Participants (N = 160) aged 18-50 with elevated psychological distress (K10 > 21) will be randomized (1:1; block sizes 4 and 6) to:
Experimental arm: MIED - 8 weeks of weekly 2.5-hour group sessions plus daily 15-minute app-based(IMIED) home practice.
Active comparator arm: PMR - 8 weeks of structurally matched weekly 2.5-hour group sessions plus daily 15-minute audio home practice.
Assessments. Baseline (T1), post-intervention (T2, within 2 weeks after Week 8), and 1-month follow-up (online). During the intervention, brief online tracking (GAD-7, PHQ-9) occurs at Weeks 2, 4, and 6.
Neuroimaging. Multimodal EEG includes: (a) 5-minute resting-state EEG (FAA, theta power); (b) Fast Periodic Visual Stimulation (FPVS; 6 Hz base frequency, 1.2 Hz oddball for emotional faces) to index automatic emotional processing; (c) Task-based ERP ( LPP at 400-800 ms ) during emotional picture rating to index controlled emotional processing.
Primary Mechanistic Outcome. LPP early-window (400-800 ms) mean amplitude under negative stimulus conditions.
Statistical Analysis. Primary efficacy analyses will use linear mixed-effects models (LMM) under the intention-to-treat (ITT) principle. Missing data will be handled by restricted maximum likelihood (REML) assuming MAR, with multiple imputation as a sensitivity analysis. Hierarchical multiple comparison control: primary outcome (GAD-7) at α = 0.05 (two-sided); key secondary outcome (PHQ-9) reported with nominal and corrected p-values; remaining psychological and EEG measures corrected by Benjamini-Hochberg FDR.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
This study's planned enrollment of 160 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Browse Depression studies →Peking University is the lead sponsor of 420 studies on the registry; 124 are open to participants now.
Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A structured 8-week Progressive Muscle Relaxation program matched to MIED in frequency, duration, and format: weekly 2.5-hour group sessions plus daily 15-minute audio home practice. Participants progress from tension-release of major muscle groups to full-body relaxation.
Behavioral: PMR
A standardized 8-week transdiagnostic mindfulness program: weekly 2.5-hour group sessions plus daily 15-minute app-based home practice (iMIED). Content includes mindful breathing, body scan, mindful walking, and loving-kindness meditation.
Behavioral: MIED
A standardized 8-week transdiagnostic mindfulness intervention (MIED) based on the Unified Protocol and contemporary mindfulness theory. Participants attend weekly 2.5-hour group sessions and complete daily 15-minute home practice via a mobile app (iMIED). Core practices include mindful breathing, body scan, mindful walking, and loving-kindness meditation. The program emphasizes four key strategies: engagement with life, distress tolerance, cognitive flexibility, and emotion-driven behavioral regulation. All sessions follow a structured manual to ensure fidelity.
A structured 8-week Progressive Muscle Relaxation program matched to MIED in frequency, duration, and format. Participants attend weekly 2.5-hour group sessions and complete daily 15-minute audio-guided home practice. The program progresses from systematic tension-release of major muscle groups to full-body relaxation, controlling for non-specific therapeutic factors (group support, time, expectancy). All sessions are manualized to ensure consistent delivery.
Generalized Anxiety Disorder-7(GAD-7)
The GAD-7 is a 7-item self-report measure of anxiety symptom severity over the past 2 weeks. Total scores range from 0 to 21. The primary analysis examines the Group × Time interaction using linear mixed-effects models across all six assessment points (Weeks 0, 2, 4, 6, 8, and 12).
Time frame: Baseline (T1, Week 0), Week 2, Week 4, Week 6, post-intervention (T2, Week 8), and 1-month follow-up (Week 12)
Patient Health Questionnaire(PHQ-9)
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure assessing the severity of depressive symptoms over the past two weeks. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms (worse outcome).
Time frame: Baseline (T1, Week 0), Week 2, Week 4, Week 6, post-intervention (T2, Week 8), and 1-month follow-up (Week 12)
Five Facet Mindfulness Questionnaire-20 (FFMQ-20)
The Five Facet Mindfulness Questionnaire-20 (FFMQ-20) is a 20-item self-report measure assessing trait mindfulness across five facets. Total scores range from 20 to 100, with higher scores indicating greater mindfulness (better outcome).
Time frame: Baseline (T1,week 0) and post-intervention (T2, Week 8)
Distress Tolerance Scale (DTS)
The Distress Tolerance Scale (DTS) is a 15-item self-report measure assessing an individual's perceived ability to tolerate and manage emotional distress. Total scores range from 15 to 75, with higher scores indicating greater distress tolerance (better outcome).
Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)
Cognitive Flexibility Inventory (CFI)
The Cognitive Flexibility Inventory (CFI) is a 20-item self-report measure assessing cognitive flexibility. Total scores range from 20 to 140, with higher scores indicating greater cognitive flexibility (better outcome).
Time frame: Baseline (T1,week0) and post-intervention (T2,week8)
Excessive Emotional Behavior Scale (EEBS)
EEBS is a self-report measure assessing the tendency to engage in excessive emotional behaviors in response to emotional distress. Higher scores indicate greater levels of excessive emotional behavior.
Time frame: Baseline (T1,week 0) and post-intervention (T2,week8)
Engagement with Life Scale (ELS)
ELS is a self-report measure assessing the extent to which individuals engage in meaningful and valued life activities despite experiencing emotional distress. Higher scores indicate greater engagement with life.
Time frame: Baseline (T1,week0) and post-intervention (T2,week8)
Chinese Perceived Stress Scale (CPSS)
The Chinese Perceived Stress Scale-14 (CPSS-14) is a 14-item self-report measure assessing perceived stress during the past month. Total scores range from 0 to 56, with higher scores indicating greater perceived stress (worse outcome).
Time frame: baseline(T1,week 0),post-intervention(T2,week8)
Late Positive Potential (LPP) early window (400-800 ms)
Late Positive Potential (LPP; 400-800 ms mean amplitude) is an ERP component reflecting sustained controlled processing of emotional stimuli. Mean LPP amplitude within the 400-800 ms time window will be quantified at CPz, Cz, P3, Pz, and P4 during a 20-minute emotional picture rating task. Based on the best available evidence and theoretical rationale from previous mindfulness and emotion regulation studies, LPP was selected as a candidate mechanistic outcome.
Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)
Frontal Alpha Asymmetry (FAA)
Frontal Alpha Asymmetry (FAA; 8-13 Hz log-transformed alpha power difference) is a resting-state EEG measure of frontal hemispheric asymmetry, associated with affective processing, emotion regulation, and approach-withdrawal motivational tendencies. FAA will be calculated as the log-transformed alpha power difference between homologous frontal electrode pairs during a 5-minute resting-state EEG recording. The primary specification is FAAln = ln(F4) - ln(F3), using absolute alpha power at F3/F4. As an exploratory specification, FAAlnrel = ln\[rel(F4)\] - ln\[rel(F3)\] will also be examined, where rel denotes alpha power divided by total (1-45 Hz) power at the same electrode. This addition does not alter the primary specification and was made prior to any analysis of post-intervention EEG data and prior to unblinding of group allocation.
Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)
Frontal theta power
Frontal theta power (4-8 Hz) is a resting-state EEG measure associated with cognitive control, attentional regulation, and emotion regulation. Absolute or relative theta power within the 4-8 Hz frequency band will be quantified from frontal electrodes (e.g., Fz, F3, and F4) during a 5-minute resting-state EEG recording. Based on the best available evidence and theoretical rationale from previous mindfulness and cognitive control studies, frontal theta power was selected as a candidate mechanistic outcome.
Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)
Fast Periodic Visual Stimulation Signal-to-Noise Ratio (FPVS-SNR)
Fast Periodic Visual Stimulation Signal-to-Noise Ratio (FPVS-SNR) is an EEG-derived measure quantifying neural responses to periodically presented emotional visual stimuli. Change in FPVS-SNR from baseline to post-intervention will be assessed during the emotional fast periodic visual stimulation task.Based on the best available evidence and theoretical rationale, FPVS-SNR was selected as a candidate mechanistic outcome to assess changes in visual emotional processing following the intervention.
Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)
Kessler Psychological Distress Scale (K10)
The Kessler Psychological Distress Scale (K10) is a 10-item self-report measure assessing non-specific psychological distress during the past four weeks. Total scores range from 10 to 50, with higher scores indicating greater psychological distress (worse outcome).
Time frame: Baseline (T1,week 0) and post-intervention (T2, Week 8)]
Meditation-Related Adverse Events Scale (MRAES-MBP)
The MRAES-MBP is a self-report measure assessing meditation-related adverse events experienced during participation in mindfulness-based programs, including their occurrence and severity.
Time frame: Week 2, Week 4, Week 6, and Week 8
Simplified adverse events questionnaire
A simplified safety monitoring questionnaire administered biweekly to the PMR group to assess somatic discomfort and emotional reactions related to muscle relaxation practice.
Time frame: Week 2, Week 4, Week 6, and Week 8
Credibility/Expectancy Questionnaire (CEQ) score
A 6-item measure of intervention credibility and improvement expectancy, administered to assess and control for non-specific expectancy effects as a covariate in primary efficacy analyses.
Time frame: After the first group session (Week 1)
Spectral Parameterization (FOOOF/specparam)-Derived Aperiodic and Periodic Parameters
Spectral parameterization (FOOOF/specparam)-derived measures are exploratory resting-state EEG outcomes obtained by decomposing the neural power spectrum into periodic (oscillatory) and aperiodic (1/f-like) components (Donoghue et al., 2020). From 5-minute resting-state EEG recordings, the aperiodic exponent and offset will be estimated at midline electrodes Oz and Cz (2-40 Hz fit). Oscillatory alpha-peak parameters (center frequency, power, bandwidth) from the same parameterization will also be examined. Model-fit indices and peak-detection information will be used for quality control, not as intervention outcomes. Emerging evidence links aperiodic activity to arousal, affective processing, and meditation-related states; these measures are hypothesis-generating outcomes of intervention-related change. This exploratory analysis was added during a registration revision, prior to any analysis of post-intervention EEG data and prior to unblinding of group allocation.
Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)
Plan to share: No — Individual participant data (IPD) will not be made publicly available because the study involves sensitive mental health data and participant privacy must be protected. Requests for additional information regarding the study may be directed to the corresponding author.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.